The FDA says the latest vaccine formulae "closely targets currently circulating variants" to give better protection against ...
U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected ...
A third COVID-19 vaccine will be available shortly as Novavax joins Pfizer/BioNTech and Moderna in targeting variants that ...
Stephane Bancel, Moderna CEO, joins 'Squawk Box' to discuss Moderna's recent stock performance, what could explain the stock's underperformance, and much more.
The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID ...
The protein-based shot represents a non-mRNA option for the 2024-2025 season, and follows the agency's recent approvals and ...
The updated vaccine is designed to better protect against “serious consequences of COVID-19″ such as hospitalization and ...
This year’s approval for the updated mRNA vaccines comes much sooner than happened in 2023, when fall vaccines were authorized on Sept. 11. The latest shots from Moderna and Pfizer will now target a ...
Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in ...
The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID ...
FDA staffers have not returned to roughly 2,000 pharmaceutical manufacturing firms to conduct surveillance inspections since ...
Last year’s inspection numbers were down almost 40% from the pre-pandemic period, when the FDA averaged about 4,300 annual ...